Gene expression analysis in N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mice model of Parkinson's disease using cDNA microarray:: effect of R-apomorphine

被引:144
作者
Grünblatt, E
Mandel, S
Maor, G
Youdim, MBH
机构
[1] Technion Israel Inst Technol, Fac Med,Dept Pharm, Eve Topf US Natl Parkinsons Fdn Ctr Neurodegener, Bruce Rappaport Family Res Inst, IL-31096 Haifa, Israel
[2] Eve Topf & US Natl Parkinsons Fdn Ctr Neurodegene, Bruce Rappaport Family Res Inst, Dept Cell Biol, Haifa, Israel
关键词
apomorphine; cDNA expression array; in situ hybridization; N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Parkinson's disease; quantitative real-time RT-PCR;
D O I
10.1046/j.1471-4159.2001.00397.x
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
To establish the possible roles of oxidative stress, inflammatory processes and other unknown mechanisms in neurodegeneration, we investigated brain gene alterations in N-methyl-4-phenyl-1,2,3.6-tetrahydropyridine (MPTP) mice model of Parkinson's disease using Atlas mouse cDNA expression array membrane. The expression of 51 different genes involved in oxidative stress, inflammation, glutamate and neurotrophic factors pathways as well as in still undefined processes, such as cell cycle regulators and signal transduction molecules, was differentially affected by the treatment. The present study indicates the involvement of an additional cascade of events that might act in parallel to oxidative stress and inflammation to converge eventually into a common pathway leading to neurodegeneration. The attenuation of these gene changes by R-apomorphine, an iron chelator-radical scavenger drug, supports our previous findings in vivo where R-apomorphine was neuroprotective.
引用
收藏
页码:1 / 12
页数:12
相关论文
共 44 条
[1]  
Backert S, 1999, INT J CANCER, V82, P868, DOI 10.1002/(SICI)1097-0215(19990909)82:6<868::AID-IJC16>3.0.CO
[2]  
2-W
[3]  
BERNHEIMER H, 1973, J NEUROL SCI, V20, P415, DOI 10.1016/0022-510X(73)90175-5
[4]   IL-1β, IL-2, IL-6 and TNF-α production by peripheral blood mononuclear cells from patients with Parkinson's disease [J].
Bessler, H ;
Djaldetti, R ;
Salman, H ;
Bergman, M ;
Djaldetti, M .
BIOMEDICINE & PHARMACOTHERAPY, 1999, 53 (03) :141-145
[5]   Oxidative stress and nuclear factor-κB activation -: A reassessment of the evidence in the light of recent discoveries [J].
Bowie, A ;
O'Neill, LAJ .
BIOCHEMICAL PHARMACOLOGY, 2000, 59 (01) :13-23
[6]   THE NONCOMPETITIVE NMDA-RECEPTOR ANTAGONIST MK-801 PREVENTS THE MASSIVE RELEASE OF GLUTAMATE AND ASPARTATE FROM RAT STRIATUM INDUCED BY 1-METHYL-4-PHENYLPYRIDINIUM (MPP+) [J].
CARBONI, S ;
MELIS, F ;
PANI, L ;
HADJICONSTANTINOU, M ;
ROSSETTI, ZL .
NEUROSCIENCE LETTERS, 1990, 117 (1-2) :129-133
[7]   DNA microarrays in drug discovery and development [J].
Debouck, C ;
Goodfellow, PN .
NATURE GENETICS, 1999, 21 (Suppl 1) :48-50
[8]  
DeRisi J, 1996, NAT GENET, V14, P457
[9]   Tissue- and cell type-specific expression of cytochrome P450 1A1 and cytochrome P450 1A2 mRNA in the mouse localized in situ hybridization [J].
Dey, A ;
Jones, JE ;
Nebert, DW .
BIOCHEMICAL PHARMACOLOGY, 1999, 58 (03) :525-537
[10]   NMDA RECEPTOR ACTIVATION INDUCES NITRIC-OXIDE SYNTHESIS FROM ARGININE IN RAT-BRAIN SLICES [J].
GARTHWAITE, J ;
GARTHWAITE, G ;
PALMER, RMJ ;
MONCADA, S .
EUROPEAN JOURNAL OF PHARMACOLOGY-MOLECULAR PHARMACOLOGY SECTION, 1989, 172 (4-5) :413-416